Skip to content

Incidence of bleeding in Covid-19 patients.

Incidence of Major and Clinically Relevant Non-Major Bleeding (CRNMB) Among Covid 19 pneumonia Patients Receiving Therapeutic Heparin: A Retrospective Cohort Study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2021/07/034867
Enrollment
122
Registered
2021-07-15
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J09- Influenza due to certain identified influenza viruses

Interventions

None listed

Sponsors

PGIMER Chandigarh
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.All patients with age 18 years to 65 years. 2.Confirmed COVID 19 from nasopharyngeal swap by Real time Polymerase chain reaction (RT PCR) 3.Patients admitted to ICU and treated with therapeutic dosage of anti-coagulants. Therapeutic anticoagulation includes patients who receive LMWH at curative dose (100 IU/kg/12 h SC based on actual weight, without exceeding 10,000 IU/12 h or UFH 500 IU/kg/24 h if creatinine clearance

Exclusion criteria

Exclusion criteria: a)Patients who received prophylactic dose anticoagulants. This includes patients treated with standard or reinforced prophylactic dosage of heparin (low molecular weight heparin LMWH-enoxaparinâ??up to 6000 IU/12 h SC in obese patients or unfractionated heparin UFH 200 IU/kg/24 h if creatinine clearance b)Patients with a known bleeding disorder or evidence of active bleeding at the time of admission. c)Any contraindication to the use of Heparin.

Design outcomes

Primary

MeasureTime frame
The aim of the study will be to assess the incidence of major and clinically relevant nonmajor bleeding among Covid 19 pneumonia patients receiving therapeutic heparin.Timepoint: Day of Icu admission to discharge/death from ICU, could be 2-4 weeks

Secondary

MeasureTime frame
a)Incidence of each type of thrombotic/ischemic events occurring during ICU stay b)Platelet count and coagulation tests including prothrombin time (PT), antithrombin activity (AT), fibrinogen, D-dimers and activated partial thromboplastin time (aPTT). c)Elevated liver enzymes (AST, ALT more than 3times the normal value) d)Need for mechanical ventilation, e)Duration of ICU stay f)Duration of hospital stay Timepoint: Day of Icu admission to discharge/death from ICU,could be 2-4 weeks.

Countries

India

Contacts

Public ContactAjay Singh

Post Graduate Institute of Medical Education & Research Chandigarh India

ajay.ydv2509@gmail.com9999276845

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026